Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 47Glioblastoma 47Breast Neoplasms 40Esophageal Neoplasms 36Rectal Neoplasms 35Carcinoma, Non-Small-Cell Lung 34Lung Neoplasms 33Head and Neck Neoplasms 29Squamous Cell Carcinoma of Head and Neck 26Brain Neoplasms 23Pancreatic Neoplasms 22Neoplasms 19Uterine Cervical Neoplasms 17Oropharyngeal Neoplasms 16Neoplasm Metastasis 16Gliosarcoma 16Esophageal Squamous Cell Carcinoma 16Glioma 15Sarcoma 14Melanoma 14Stomach Neoplasms 12Adenocarcinoma Of Esophagus 12Lymphoma, Follicular 9Carcinoma, Squamous Cell 9Mouth Neoplasms 8Lymphoma, B-Cell, Marginal Zone 8Anus Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Leukemia, Myeloid, Acute 7Endometrial Neoplasms 7

Interventions

Magnetic Resonance Spectroscopy 5luprolide acetate gel depot 3Radiotherapy 3Radiosurgery 3Radiation 3Leuprolide 3Goserelin 3relugolix 2gallium 68 PSMA-11 2enzalutamide 2acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 2Triptorelin Pamoate 2radium Ra 223 dichloride 1niraparib 1histrelin 1fluciclovine F-18 1flibanserin 1entinostat 1darolutamide 1bicalutamide 1atezolizumab 1apalutamide 1abiraterone 1X-Rays 1Watchful Waiting 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Specimen Handling 1Salicylic Acid 1Receptors, Bombesin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Prostate Adenocarcinoma × Radiation × Clear all
NCT03274687 2026-05-20

Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer

NRG Oncology

Phase 3 Completed
296 enrolled 29 charts
Genitourinary

Prostate Adenocarcinoma

NCT05050084 2026-05-04

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

NRG Oncology

Phase 3 Active not recruiting
2,050 enrolled
Genitourinary

Prostate Adenocarcinoma

NCT04175431 2025-12-18

Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study

University of Washington

Phase 2 Recruiting
100 enrolled
Genitourinary

Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡